Genetic Signatures Ltd (GSS) - Total Assets
Based on the latest financial reports, Genetic Signatures Ltd (GSS) holds total assets worth AU$49.04 Million AUD (≈ $34.70 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See current stock price of Genetic Signatures Ltd for real-time trading data and today's change.
Genetic Signatures Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Genetic Signatures Ltd's total assets have evolved over time, based on quarterly financial data. Also see Genetic Signatures Ltd (GSS) cash flow conversion for how efficiently the company converts equity into cash flow.
Genetic Signatures Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Genetic Signatures Ltd's total assets of AU$49.04 Million consist of 87.8% current assets and 12.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 13.7% |
| Accounts Receivable | AU$3.38 Million | 6.2% |
| Inventory | AU$9.06 Million | 16.6% |
| Property, Plant & Equipment | AU$6.66 Million | 12.2% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Genetic Signatures Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Genetic Signatures Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genetic Signatures Ltd's current assets represent 87.8% of total assets in 2025, an increase from 87.1% in 2013.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2025, down from 16.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 16.6% of total assets.
Genetic Signatures Ltd Competitors by Total Assets
Key competitors of Genetic Signatures Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
INOVIQ LTD.
F:EGQ0
|
Germany | €21.71 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €685.34K |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$584.37K |
|
Abingdon Health Plc
LSE:ABDX
|
UK | GBX10.55 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
Genetic Signatures Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.99 | 13.74 | 9.16 |
| Quick Ratio | 7.20 | 11.86 | 7.20 |
| Cash Ratio | 3.60 | 10.87 | 6.33 |
| Working Capital | AU$38.18 Million | AU$47.81 Million | AU$46.78 Million |
Genetic Signatures Ltd - Advanced Valuation Insights
This section examines the relationship between Genetic Signatures Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.41 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -18.8% |
| Total Assets | AU$54.63 Million |
| Market Capitalization | $13.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genetic Signatures Ltd's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genetic Signatures Ltd's assets decreased by 18.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genetic Signatures Ltd (2013–2025)
The table below shows the annual total assets of Genetic Signatures Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$54.63 Million ≈ $38.65 Million |
-18.81% |
| 2024-06-30 | AU$67.29 Million ≈ $47.61 Million |
+37.10% |
| 2023-06-30 | AU$49.08 Million ≈ $34.73 Million |
-17.73% |
| 2022-06-30 | AU$59.65 Million ≈ $42.21 Million |
+10.37% |
| 2021-06-30 | AU$54.05 Million ≈ $38.24 Million |
+8.71% |
| 2020-06-30 | AU$49.72 Million ≈ $35.18 Million |
+309.85% |
| 2019-06-30 | AU$12.13 Million ≈ $8.58 Million |
-16.97% |
| 2018-06-30 | AU$14.61 Million ≈ $10.34 Million |
-17.35% |
| 2017-06-30 | AU$17.67 Million ≈ $12.51 Million |
+196.40% |
| 2016-06-30 | AU$5.96 Million ≈ $4.22 Million |
-23.55% |
| 2015-06-30 | AU$7.80 Million ≈ $5.52 Million |
-52.86% |
| 2014-06-30 | AU$16.55 Million ≈ $11.71 Million |
+1708.78% |
| 2013-06-30 | AU$914.85K ≈ $647.32K |
-- |
About Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, a… Read more